Abivax (ABVX) Current Assets (2021 - 2026)

Abivax's Current Assets history runs 6 years deep, the most recent figure standing at $600.9 million for Q1 2026.

• On a quarterly basis, Current Assets rose 330.56% year-over-year to $600.9 million in Q1 2026; TTM through Mar 2026 was $600.9 million, a 330.56% increase from a year earlier, with the FY2025 full-year figure at $641.7 million, up 247.37% from the prior year.
• Current Assets declined to $600.9 million in Q1 2026 per ABVX's latest filing, from $641.7 million in the prior quarter.
• Across five years, Current Assets topped out at $724.0 million in Q3 2025 and bottomed at $36.9 million in Q4 2022.
• The 5-year median for Current Assets is $261.7 million (2024), against an average of $332.5 million.
• Across the five-year window, Current Assets soared 733.54% in 2023 and sank 62.75% in 2025, its largest moves.
• Year by year, Current Assets stood at $36.9 million in 2022, then surged by 733.54% to $307.7 million in 2023, then plunged by 40.73% to $182.4 million in 2024, then surged by 251.84% to $641.7 million in 2025, then dropped by 6.36% to $600.9 million in 2026.
• Per Business Quant, the three latest ABVX Current Assets figures stand at $600.9 million (Q1 2026), $641.7 million (Q4 2025), and $724.0 million (Q3 2025).